Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Grössmann N. Abemaciclib (Verzenio®) in combination with fulvestrant for treatment of HR-positive, HER2-negative advanced breast cancer (ABC) Vienna: Ludwig Boltzmann Institut fuer Health Technology Assessment (LBIHTA). DSD: Horizon Scanning in Oncology. 2017 Authors' conclusions In conclusion, the treatment with abemaciclib offers a statistically significant improvement in PFS (+7.1 months) and ORR (+19.1%) with an inferior safety profile at high costs. Due to the immature OS data and the missing QoL results, there is a need for long-term data to avoid a systematic overestimation of the treatment effect of abemaciclib. In the future, the identification of a robust predictive biomarker to identify the most suitable patients will be crucial for the class of CDK4/6 inhibitors. Finally, direct comparisons of abemaciclib to palbociclib and ribociclib are essential to investigate which treatment option is most beneficial for HR-positive, HER2-negative ABC patients. Indexing Status Subject indexing assigned by CRD MeSH Aminopyridines; Benzimidazoles; Breast; Breast Neoplasms; Estradiol; Humans; fulvestrant Language Published English Country of organisation Austria English summary An English language summary is available. Address for correspondence Ludwig Boltzmann Institute fuer Health Technology Assessment (LBI-HTA), Garnisongasse 7 rechte Stiege Mezzanin (Top 20), 1090 Vienna, Austria. Tel: +43 1 236 8119 - 0 Fax: +43 1 236 8119 - 99 AccessionNumber 32017000424 Date abstract record published 06/11/2017 |
